Improvement effects of a novel Chinese herbal formula in imiquimod and IL-23-stimulated mouse models of psoriasis

Lan Wang,Yao-Xing Dou,Qiu-Xia Yu,Zhen Hu,Siu-Po Ip,Yan-Fang Xian,Zhi-Xiu Lin

DOI: https://doi.org/10.1186/s13020-024-00951-9

IF: 4.546

2024-06-12

Chinese Medicine

Abstract:Psoriasis is a long-term inflammatory skin disease. A novel herbal formula containing nine Chinese herbal medicines, named Inflammation Skin Disease Formula (ISDF), has been prescribed in clinics for decades.

pharmacology & pharmacy,integrative & complementary medicine

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the efficacy and mechanism of a novel traditional Chinese medicine compound (Inflammation Skin Disease Formula, ISDF) in the treatment of psoriasis. Specifically, the researchers assess the therapeutic effects of ISDF on psoriasis using mouse models induced by imiquimod (IMQ) and interleukin-23 (IL-23), and reveal its pharmacokinetic characteristics.

### Main Research Questions:
1. **Efficacy Evaluation of ISDF**: Investigate the anti-psoriatic effects of ISDF in IMQ and IL-23 induced psoriasis mouse models.
2. **Mechanism Exploration**: Uncover the mechanism of ISDF in psoriasis treatment, particularly its impact on the IL-23/Th17 axis, NF-κB signaling pathway, and MAPK signaling pathway.
3. **Pharmacokinetic Study**: Evaluate the absorption, distribution, and metabolism of ISDF in rats to determine its feasibility for long-term application.

### Research Background:
- Psoriasis is a chronic inflammatory skin disease characterized by silvery scales, erythema, and other symptoms.
- Current common treatments include topical steroids and oral glucocorticoids, but these methods have side effects.
- Biologics such as ustekinumab have significant efficacy but are costly, limiting their widespread use.
- Traditional Chinese medicine compounds are potential alternatives for psoriasis treatment due to their high safety and low cost.

### Research Methods:
- **Animal Model**: Use IMQ and IL-23 induced psoriasis mouse models.
- **Administration Method**: ISDF is administered orally and compared with the positive control drug dexamethasone (DXM).
- **Evaluation Indicators**: Include mouse body weight, skin thickness, psoriasis area and severity index (PASI), histopathological examination of skin tissues, and detection of inflammatory cytokines.

### Main Results:
- **Anti-psoriatic Effects of ISDF**: ISDF significantly alleviated psoriasis symptoms in IMQ and IL-23 induced mouse models, as evidenced by reduced PASI scores and decreased epidermal thickness.
- **Mechanism of Action**: ISDF reduced the release of inflammatory cytokines by inhibiting the activation of the IL-23/Th17 axis, NF-κB signaling pathway, and MAPK signaling pathway.
- **Pharmacokinetics**: ISDF showed slow absorption and metabolism in rats, making it suitable for long-term application.

### Conclusion:
ISDF demonstrated significant anti-psoriatic effects in IMQ and IL-23 induced psoriasis mouse models, primarily by inhibiting the IL-23/Th17 axis and downstream NF-κB and MAPK signaling pathways. ISDF has favorable pharmacokinetic properties, making it suitable for long-term use and a promising new option for psoriasis treatment.